1 |
SWERDLOW S H, CAMPO E, PILERI S A, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390.
|
2 |
PFREUNDSCHUH M, KUHNT E, TRÜMPER L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group[J]. Lancet Oncol, 2011, 12(11): 1013-1022.
|
3 |
COIFFIER B, THIEBLEMONT C, VAN DEN NESTE E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte[J]. Blood, 2010, 116(12): 2040-2045.
|
4 |
GISSELBRECHT C, SCHMITZ N, MOUNIER N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma[J]. J Clin Oncol, 2012, 30(36): 4462-4469.
|
5 |
CHESON B D, FISHER R I, BARRINGTON S F, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification[J]. J Clin Oncol, 2014, 32(27): 3059-3068.
|
6 |
YI J H, JEONG S H, KIM S J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from two prospective Korean cohorts[J]. Cancer Res Treat, 2023, 55(1): 325-333.
|
7 |
GISSELBRECHT C, GLASS B, MOUNIER N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era[J]. J Clin Oncol, 2010, 28(27): 4184-4190.
|
8 |
CRUMP M, KURUVILLA J, COUBAN S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: ncic-CTG LY.12[J]. J Clin Oncol, 2014, 32(31): 3490-3496.
|
9 |
EL-GALALY T C, CHEAH C Y, KRISTENSEN D, et al. Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas[J]. Acta Oncol, 2020, 59(7): 766-774.
|
10 |
DREGER P, FENSKE T S, MONTOTO S, et al. Cellular immunotherapy for refractory diffuse large B cell lymphoma in the chimeric antigen receptor-engineered T cell era: still a role for allogeneic transplantation?[J]. Biol Blood Marrow Transplant, 2020, 26(4): e77-e85.
|
11 |
ALBANYAN O, CHAVEZ J, MUNOZ J. The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma[J]. Ther Adv Hematol, 2022, 13: 20406207221141511.
|
12 |
WANG T, XU L, GAO L, et al. Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: a single-center, retrospective, cohort study[J]. Hematol Oncol, 2022, 40(4): 637-644.
|
13 |
ZINZANI P L, RODGERS T, MARINO D, et al. RE-MIND: comparing tafasitamab + lenalidomide (L-MIND) with a real-world lenalidomide monotherapy cohort in relapsed or refractory diffuse large B-cell lymphoma[J]. Clin Cancer Res, 2021, 27(22): 6124-6134.
|
14 |
HAMADANI M, RADFORD J, CARLO-STELLA C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma[J]. Blood, 2021, 137(19): 2634-2645.
|
15 |
PAPAGEORGIOU S G, THOMOPOULOS T P, LIASKAS A, et al. Monoclonal antibodies in the treatment of diffuse large B-cell lymphoma: moving beyond rituximab[J]. Cancers (Basel), 2022, 14(8): 1917.
|
16 |
BOURBON E, SALLES G. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma[J]. Expert Opin Investig Drugs, 2020, 29(10): 1079-1088.
|
17 |
WULLENKORD R, BERNING P, NIEMANN A L, et al. The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis[J]. Ann Hematol, 2021, 100(11): 2733-2744.
|
18 |
EPPERLA N, HAMADANI M, RELJIC T, et al. Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: a systematic review and meta-analysis[J]. Cancer, 2019, 125(24): 4417-4425.
|
19 |
HUANG H H, WEN Y C, CHEN H M, et al. Rituximab maintenance improves overall survival in follicular lymphoma: a retrospective nationwide real-world analysis from Taiwan Cancer Registry Database[J]. Cancer Med, 2018, 7(8): 3582-3591.
|
20 |
HALWANI A S, RASMUSSEN K M, PATIL V, et al. Maintenance rituximab in veterans with follicular lymphoma[J]. Cancer Med, 2020, 9(20): 7537-7547.
|
21 |
ZHOU X, MA T, ZHANG Y, et al. Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: a meta-analysis[J]. PLoS One, 2017, 12(3): e0174648.
|